CD40LG and cancer: Another well-studied candidate is PAT-SM6, a human IgM monoclonal antibody targeting a cancer-specific isoform of glucose-regulated protein 78 (GRP78), with additional binding to low-density lipoprotein (LDL) complexes through GRP78-mediated interactions (43) (Table 1).